twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2011
vol. 113
 
Share:
Share:
abstract:
Original paper

Quality of life in patients with age-related macular degeneration – Medical and social problem

Maria Muzyka-Woźniak
1, 2
,
Marta Misiuk-Hojło
1
,
Alicja Wesołowska
2

  1. Katedra i Klinika Okulistyki Akademii Medycznej we Wrocławiu
  2. Ośrodek Okulistyki Klinicznej „Spektrum” we Wrocławiu
Klinika Oczna 2011, 113 (2): 161-164
Online publish date: 2011/06/29
View full text Get citation
 
Introduction
Age-related macular degeneration (AMD) is a leading cause of blindness over the age of 50 in western countries. People with AMD are suffering from serious vision-related disability and their social life is compromised. Purpose: The aim of our study was to assess quality of life (QoL) in patients with exudative AMD.

Material and methods
The study group was 100 patients treated for AMD with anti-VEGF therapy. The control group were 30 age and sex matched subjects without ophthalmic disorders. QoL was assessed with National Eye Institute Visual Function Questionnaire (NEI VFQ – 25).

Results
There was statistically significant difference in QoL overall score between study group and control group. Patients with AMD obtained 51.1 (± 20.5 ) overall score, control group reached 83.7 (± 11.7) overall score, p = 0.001. Detailed analysis of study group revealed low acceptance of the disease and strong dependency.

Conclusions
QoL in patients with AMD assessed with NEI VFQ-25, is significantly impaired. Low quality of life and difficulties in performing daily activities point at the need of formal psychological and social care.

keywords:

exudative age related macular degeneration (AMD), quality of life (QoL), anti-VEGF therapy

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.